Pharmaceutical Technology on MSN3d
Novo Nordisk earmarks $2bn for Chinese “triple G” weight loss shot
Novo Nordisk has acquired the global rights to United Laboratories’ triple-agonist weight-loss and diabetes drug in a deal ...
Novo Nordisk Stock (NVO) Sees Its Largest Monthly Drop Since 2002
Novo Nordisk’s (NVO) stock has dropped by 25% in March (on the Copenhagen exchange) to put it on track for its biggest ...
BioSpace12h
Novo’s Obesity Pipeline Keeps Evolving With up to $1B Lexicon Deal
Lexicon's LX9851 targets ACSL5, a liver enzyme involved in fat metabolism that helps moderate fat accumulation and slow down ...
Novo shares on track for biggest monthly fall since 2002, investor worries grow
Novo Nordisk shares have fallen 25% so far in March and are on track for their biggest monthly drop since July 2002, as ...
Novo Nordisk Down 15% in March: Is This a Buying Opportunity?
Despite the current downward trend of NVO, it is a good stock to add to one's portfolio for long-term gains due to strong ...
Healthy Returns: Novo Nordisk scoops up Chinese obesity drug to compete with Eli Lilly
Novo Nordisk is taking aim at Eli Lilly with a new obesity drug deal. Meanwhile, a survey shows doctors’ perception of the ...
New Atlas3d
Next-gen weight-loss drugs will be here within 12 months
It was only a matter of time until the GLP-1 receptor agonist drugs like Ozempic and Wegovy were superseded, and now it looks ...
Germany’s SAP Overtakes Wegovy Maker Novo Nordisk as Europe’s Most Valuable Company
The business-software group claimed the top spot as Europe’s largest company by market value, dethroning Wegovy maker Novo ...